These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23934770)

  • 1. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
    Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
    J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
    Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
    J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
    Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
    J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
    Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
    Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
    J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
    Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
    J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
    Basson AE; Rhee SY; Parry CM; El-Khatib Z; Charalambous S; De Oliveira T; Pillay D; Hoffmann C; Katzenstein D; Shafer RW; Morris L
    Antimicrob Agents Chemother; 2015 Feb; 59(2):960-71. PubMed ID: 25421485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.